Physician profile
Matthew L Ortman
NPI 1366582116
$7,210.41
in general payments reported to CMS, 2019-2025
31 companies · $1,710 in 2025
The $1,710 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $462 · 2021: $540 · 2022: $724 · 2023: $1,392 · 2024: $1,482 · 2025: $1,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,583.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,461.61 | 2019-2025 | Aveir, Tacticath, Triclip |
| Biosense Webster, INC. | $1,003.37 | 2021-2025 | Carto 3, Nuvision Ice Catheter, Qdot Micro Catheter |
| Atricure, INC. | $510.98 | 2022-2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Amgen INC. | $304.21 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $285.46 | 2019-2024 | Xarelto |
| Impulse Dynamics (USA) INC. | $167.03 | 2022-2025 | Optimizer |
| Pfizer INC. | $166.99 | 2019-2024 | |
| Boston Scientific Corporation | $164.35 | 2019-2025 | General - Therapies |
| Genzyme Corporation | $160.00 | 2020 | |
| Medtronic, INC. | $148.54 | 2022-2023 | Linq II, Azure Xt Dr Mri Surescan, Micra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $132.38 | 2019-2020 | |
| Philips North America LLC | $131.17 | 2022-2025 | (5044) Mcot, Extended Holter, (5050) Extended Holter |
| Novartis Pharmaceuticals Corporation | $112.27 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $67.33 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $43.37 | 2021-2023 | Verquvo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $34.43 | 2024-2025 | |
| Covidien LP | $32.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.30 | 2023-2025 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $31.18 | 2023 | Arcalyst |
| Biohaven Pharmaceuticals, INC. | $29.86 | 2021 | |
| Teleflex LLC | $23.74 | 2025 | Turnpike |
| Cvrx, INC. | $20.95 | 2025 | Barostim Neo System |
| Elutia, INC. | $19.12 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.80 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.65 | 2025 | |
| Stryker Corporation | $17.42 | 2025 | Flowtriever |
| Esperion Therapeutics, INC. | $16.65 | 2025 | Nexletol |
| Chiesi USA, INC. | $16.48 | 2024 | Kengreal |
| E.R. Squibb & Sons, L.L.C. | $14.72 | 2019 | |
| Kestra Medical Technology Services, INC. | $14.72 | 2024 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ortman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.